<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03522246</url>
  </required_header>
  <id_info>
    <org_study_id>CO-338-087/GOG-3020/ENGOT-ov45</org_study_id>
    <nct_id>NCT03522246</nct_id>
  </id_info>
  <brief_title>A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy</brief_title>
  <acronym>ATHENA</acronym>
  <official_title>ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clovis Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Network of Gynaecological Oncological Trial Groups (ENGOT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Foundation Medicine</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Clovis Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm
      study evaluating rucaparib and nivolumab as maintenance treatment following response to
      front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will
      be analyzed based on homologous recombination (HR) status of tumor samples.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator assessed Progression-free survival (PFS)</measure>
    <time_frame>From randomization until disease progression (up to approximately 10 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blinded independent central review (BICR) PFS</measure>
    <time_frame>Every ~12 weeks after the start of combination treatment for ~3 years, then every ~24 weeks thereafter until disease progression. Study data collection expected to last for ~7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From enrollment to primary study completion of study (up to approximately 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>For patients with measurable disease, every ~12 weeks after the start of combination treatment for ~3 years, then every ~24 weeks thereafter until disease progression. Study data collection expected to last for ~7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>For patients with measurable disease, every ~12 weeks after the start of combination treatment for ~3 years, then every ~24 weeks thereafter until disease progression. Study data collection expected to last for ~7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-emergent Adverse Events (AEs) as assessed by CTCAE v4 (or higher) as a measure of safety and tolerability</measure>
    <time_frame>Collected from the time patient receives first dose of study drug until post treatment safety follow-up period (up to approximately 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with serious AEs as a measure of safety and tolerability</measure>
    <time_frame>Collected from the time patient receives first dose of study drug until post treatment safety follow-up period (up to approximately 10 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with laboratory abnormalities as a measure of safety and tolerability</measure>
    <time_frame>Collected from the time patient receives first dose of study drug until post treatment safety follow-up period (up to approximately 10 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1012</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Primary Peritoneal</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Newly Diagnosed</condition>
  <condition>FIGO Stage III-IV</condition>
  <condition>Partial Response</condition>
  <condition>Complete Response</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral rucaparib + intravenous (IV) nivolumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral rucaparib+IV placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral placebo+ IV nivolumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo + IV placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rucaparib</intervention_name>
    <description>Oral rucaparib will be administered twice daily</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Rubraca</other_name>
    <other_name>CO-338</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>IV nivolumab will be administered once every 4 weeks</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>Opdivo</other_name>
    <other_name>BMS-936558</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo tablets will be administered twice daily</description>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IV Infusion</intervention_name>
    <description>IV placebo will be administered once every 4 weeks</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed advanced (FIGO stage III-IV) epithelial ovarian, fallopian tube, or
             primary peritoneal cancer.

          -  Completed cytoreductive surgery, including at least a bilateral salpingo-oophorectomy
             and partial omentectomy, either prior to chemotherapy (primary surgery) or following
             neoadjuvant chemotherapy (interval debulking)

          -  Completed first-line platinum-based chemotherapy and surgery with a response, in the
             opinion of the Investigator

          -  Sufficient tumor tissue for planned analysis

          -  ECOG performance status of 0 or 1

        Exclusion Criteria:

          -  Pure sarcomas or borderline tumors or mucinous tumors

          -  Active second malignancy

          -  Known central nervous system brain metastases

          -  Any prior treatment for ovarian cancer, other than the first-line platinum regimen

          -  Evidence of interstitial lung disease or active pneumonitis

          -  Active, known or suspected autoimmune disease

          -  Condition requiring active systemic treatment with either corticosteroids (&gt;10 mg
             daily prednisone equivalent) or other immunosuppressive medications
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clovis Oncology Clinical Trial Information</last_name>
    <phone>1-855-262-3040 (USA)</phone>
    <email>clovistrials@emergingmed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clovis Oncology Clinical Trial infomration</last_name>
    <phone>+1-303-625-5160 (ex-USA)</phone>
    <email>clovistrials@emergingmed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Oncology (US Oncology Network)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bradley Monk, MD, FACS, FACOG</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London</name>
      <address>
        <city>London</city>
        <zip>WCIE 6DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rebecca Kristeleit, Msc, MBChB, FRCP, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2018</study_first_submitted>
  <study_first_submitted_qc>April 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PARP inhibitor</keyword>
  <keyword>PARPi</keyword>
  <keyword>HRD</keyword>
  <keyword>ATHENA</keyword>
  <keyword>homologous recombination</keyword>
  <keyword>DNA repair</keyword>
  <keyword>LOH</keyword>
  <keyword>DNA defect</keyword>
  <keyword>DNA anomaly</keyword>
  <keyword>Rucaparib</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>PD-1</keyword>
  <keyword>Immuno-</keyword>
  <keyword>oncology</keyword>
  <keyword>Tumor</keyword>
  <keyword>mutational</keyword>
  <keyword>burden</keyword>
  <keyword>BRCA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Rucaparib</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

